Trial Profile

Short course of pegylated GCSF [granulocyte-colony stimulating factor] (Neulasta) [pegfilgrastim] as immunomodulatory therapy for type 1 diabetes.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegfilgrastim (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Jun 2020 Results assessing change in circulating neutrophil numbers by using data from this study and other database presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
22 Mar 2012 Planned End Date changed from 1 Apr 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
22 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com